{"id":"https://openalex.org/W2538526833","doi":"https://doi.org/10.1182/blood.v120.21.2625.2625","title":"Induction of NK Cell Reactivity Against AML Cells by Fc-Engineered RANK-Ig Fusion Proteins.","display_name":"Induction of NK Cell Reactivity Against AML Cells by Fc-Engineered RANK-Ig Fusion Proteins.","publication_year":2012,"publication_date":"2012-11-16","ids":{"openalex":"https://openalex.org/W2538526833","doi":"https://doi.org/10.1182/blood.v120.21.2625.2625","mag":"2538526833"},"language":"en","primary_location":{"id":"doi:10.1182/blood.v120.21.2625.2625","doi":"https://doi.org/10.1182/blood.v120.21.2625.2625","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v120.21.2625.2625","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5046999122","display_name":"Tina Nuebling","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I8087733","display_name":"University of T\u00fcbingen","ror":"https://ror.org/03a1kwz48","country_code":"DE","type":"education","lineage":["https://openalex.org/I8087733"]}],"countries":["DE"],"is_corresponding":true,"raw_author_name":"Tina Nuebling","raw_affiliation_strings":["Department of Hematology and Oncology, Eberhard Karls University, Tuebingen, Germany,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Hematology and Oncology, Eberhard Karls University, Tuebingen, Germany,","institution_ids":["https://openalex.org/I8087733"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071199486","display_name":"Benjamin Joachim Schmiedel","orcid":"https://orcid.org/0000-0002-9103-9378","observed_orcids":["https://orcid.org/0000-0002-9103-9378"]},"institutions":[{"id":"https://openalex.org/I8087733","display_name":"University of T\u00fcbingen","ror":"https://ror.org/03a1kwz48","country_code":"DE","type":"education","lineage":["https://openalex.org/I8087733"]}],"countries":["DE"],"is_corresponding":true,"raw_author_name":"Benjamin J Schmiedel","raw_affiliation_strings":["Department of Hematology and Oncology, Eberhard Karls University, Tuebingen, Germany,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Hematology and Oncology, Eberhard Karls University, Tuebingen, Germany,","institution_ids":["https://openalex.org/I8087733"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069602567","display_name":"Miyuki Azuma","orcid":"https://orcid.org/0000-0002-3529-4585","observed_orcids":["https://orcid.org/0000-0002-3529-4585"]},"institutions":[{"id":"https://openalex.org/I125602781","display_name":"Tokyo Medical and Dental University","ror":"https://ror.org/051k3eh31","country_code":"JP","type":"education","lineage":["https://openalex.org/I125602781","https://openalex.org/I4400009020"]}],"countries":["JP"],"is_corresponding":true,"raw_author_name":"Miyuki Azuma","raw_affiliation_strings":["Department of Molecular Immunology, Tokyo Medical and Dental Univerisity, Tokyo, Japan,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Molecular Immunology, Tokyo Medical and Dental Univerisity, Tokyo, Japan,","institution_ids":["https://openalex.org/I125602781"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045281805","display_name":"Pascal Schneider","orcid":"https://orcid.org/0000-0003-0677-9409","observed_orcids":["https://orcid.org/0000-0003-0677-9409"]},"institutions":[{"id":"https://openalex.org/I97565354","display_name":"University of Lausanne","ror":"https://ror.org/019whta54","country_code":"CH","type":"education","lineage":["https://openalex.org/I97565354"]}],"countries":["CH"],"is_corresponding":true,"raw_author_name":"Pascal Schneider","raw_affiliation_strings":["Department of Biochemistry, University of Lausanne, Epalinges, Switzerland,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Biochemistry, University of Lausanne, Epalinges, Switzerland,","institution_ids":["https://openalex.org/I97565354"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002838487","display_name":"Ludger Gro\u00dfe\u2010Hovest","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I8087733","display_name":"University of T\u00fcbingen","ror":"https://ror.org/03a1kwz48","country_code":"DE","type":"education","lineage":["https://openalex.org/I8087733"]}],"countries":["DE"],"is_corresponding":true,"raw_author_name":"Ludger Grosse-Hovest","raw_affiliation_strings":["Department of Immunology, Eberhard Karls University, Tuebingen, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Immunology, Eberhard Karls University, Tuebingen, Germany","institution_ids":["https://openalex.org/I8087733"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109843451","display_name":"Lothar Kanz","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I8087733","display_name":"University of T\u00fcbingen","ror":"https://ror.org/03a1kwz48","country_code":"DE","type":"education","lineage":["https://openalex.org/I8087733"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Lothar Kanz","raw_affiliation_strings":["Department of Hematology and Oncology, Eberhard Karls University, Tuebingen, Germany,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Hematology and Oncology, Eberhard Karls University, Tuebingen, Germany,","institution_ids":["https://openalex.org/I8087733"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5026255080","display_name":"Helmut Rainer Salih","orcid":"https://orcid.org/0000-0002-6719-1847","observed_orcids":["https://orcid.org/0000-0002-6719-1847"]},"institutions":[{"id":"https://openalex.org/I8087733","display_name":"University of T\u00fcbingen","ror":"https://ror.org/03a1kwz48","country_code":"DE","type":"education","lineage":["https://openalex.org/I8087733"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Helmut R Salih","raw_affiliation_strings":["Department of Hematology and Oncology, Eberhard Karls University, Tuebingen, Germany,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Hematology and Oncology, Eberhard Karls University, Tuebingen, Germany,","institution_ids":["https://openalex.org/I8087733"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5002838487","https://openalex.org/A5045281805","https://openalex.org/A5046999122","https://openalex.org/A5069602567","https://openalex.org/A5071199486"],"corresponding_institution_ids":["https://openalex.org/I125602781","https://openalex.org/I8087733","https://openalex.org/I97565354"],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.29589326,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"120","issue":"21","first_page":"2625","last_page":"2625"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11020","display_name":"Immune Cell Function and Interaction","score":0.9976000189781189,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11020","display_name":"Immune Cell Function and Interaction","score":0.9976000189781189,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.0012000000569969416,"subfield":{"id":"https://openalex.org/subfields/2741","display_name":"Radiology, Nuclear Medicine and Imaging"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/natural-killer-cells","display_name":"natural killer cells","score":0.7739999890327454},{"id":"https://openalex.org/keywords/acute-myeloid-leukemia","display_name":"acute myeloid leukemia","score":0.9919999837875366},{"id":"https://openalex.org/keywords/rank-ligand","display_name":"RANK ligand","score":0.9430000185966492},{"id":"https://openalex.org/keywords/fc-engineered-antibody","display_name":"Fc-engineered antibody","score":0.6949999928474426},{"id":"https://openalex.org/keywords/antibody-dependent-cellular-cytotoxicity","display_name":"antibody-dependent cellular cytotoxicity","score":0.9879999756813049},{"id":"https://openalex.org/keywords/fcgammariiia","display_name":"Fc\u03b3RIIIa","score":0.8450000286102295},{"id":"https://openalex.org/keywords/immunomodulatory-cytokines","display_name":"immunomodulatory cytokines","score":0.7900000214576721},{"id":"https://openalex.org/keywords/immunotherapy","display_name":"immunotherapy","score":0.5770000219345093},{"id":"https://openalex.org/keywords/measurable-residual-disease","display_name":"minimal residual disease","score":0.8999999761581421},{"id":"https://openalex.org/keywords/allogeneic-stem-cell-transplantation","display_name":"allogeneic stem cell transplantation","score":0.9229999780654907},{"id":"https://openalex.org/keywords/tnf-family-ligands","display_name":"TNF family ligands","score":0.6389999985694885},{"id":"https://openalex.org/keywords/cytokine-milieu","display_name":"cytokine milieu","score":0.3959999978542328}],"concepts":[{"id":"https://openalex.org/C40677261","wikidata":"https://www.wikidata.org/wiki/Q21418091","display_name":"Antibody-dependent cell-mediated cytotoxicity","level":4,"score":0.8883981704711914},{"id":"https://openalex.org/C2781462264","wikidata":"https://www.wikidata.org/wiki/Q78482053","display_name":"CD16","level":5,"score":0.4603860378265381},{"id":"https://openalex.org/C154317977","wikidata":"https://www.wikidata.org/wiki/Q376266","display_name":"Cytotoxic T cell","level":3,"score":0.45903918147087097},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.45824122428894043},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.43352705240249634},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.3770114779472351},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.37680137157440186},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.35210344195365906},{"id":"https://openalex.org/C147483822","wikidata":"https://www.wikidata.org/wiki/Q103537","display_name":"Antigen","level":2,"score":0.24635463953018188},{"id":"https://openalex.org/C167672396","wikidata":"https://www.wikidata.org/wiki/Q417800","display_name":"CD8","level":3,"score":0.18845781683921814},{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.1636112630367279},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.09485021233558655},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.06668445467948914},{"id":"https://openalex.org/C114684123","wikidata":"https://www.wikidata.org/wiki/Q419458","display_name":"CD3","level":4,"score":0.06531479954719543}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood.v120.21.2625.2625","doi":"https://doi.org/10.1182/blood.v120.21.2625.2625","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v120.21.2625.2625","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9940000176429749}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2530913622","https://openalex.org/W1514772132","https://openalex.org/W2090912134","https://openalex.org/W2980114195","https://openalex.org/W4394922338","https://openalex.org/W2584568853","https://openalex.org/W1595769628","https://openalex.org/W2417802190","https://openalex.org/W2580692493","https://openalex.org/W951397387"],"abstract_inverted_index":{"Abstract":[0,1],"2625":[2],"NK":[3,21,42,72,93,104,154,217,231,243,293],"cells":[4,22,43,60,102,158,180,291],"are":[5],"cytotoxic":[6],"lymphocytes":[7],"that":[8,58,127,224],"play":[9],"an":[10,299],"important":[11,18],"role":[12],"in":[13,164,181,249,254,284],"anti-tumor":[14,35,294],"immunity.":[15],"A":[16],"clinically":[17],"feature":[19],"of":[20,34,91,96,100,115,119,162,166,196,212,264,306,311,324],"is":[23],"their":[24],"ability":[25],"to":[26,46,88,135,150,178,251,260,278,326],"mediate":[27],"antibody-dependent":[28],"cellular":[29],"cytotoxicity":[30],"(ADCC)":[31],"upon":[32],"application":[33],"antibodies.":[36],"In":[37],"acute":[38],"myeloid":[39],"leukemia":[40,290],"(AML)":[41],"largely":[44],"contribute":[45],"the":[47,63,92,116,194,210,213,261,280,304],"therapeutic":[48],"efficacy":[49],"allogenic":[50],"stem":[51],"cell":[52,73,105,218,232,244],"transplantation":[53],"(SCT).":[54],"Recently":[55],"we":[56,84,110,222],"demonstrated":[57],"AML":[59,101,157,179,207,237,252,285],"functionally":[61],"express":[62],"TNF":[64],"family":[65],"member":[66],"RANK":[67,120],"ligand":[68],"(RANKL)":[69],"which":[70],"impairs":[71],"anti-leukemia":[74],"reactivity":[75,233],"(Schmiedel":[76],"et":[77],"al.,":[78],"ASH":[79],"annual":[80],"meeting":[81],"2011).":[82],"Here":[83],"developed":[85],"a":[86,122,182,255],"strategy":[87],"combine":[89],"blocking":[90],"inhibitory":[94],"effects":[95,211],"RANKL":[97,163],"with":[98,187,226],"targeting":[99],"for":[103,292,303,309],"ADCC.":[106],"To":[107],"this":[108],"end":[109],"generated":[111],"fusion":[112,139,175,214,274],"proteins":[113,176,215],"consisting":[114],"extracellular":[117],"domain":[118],"and":[121,172,190,204,246,287],"human":[123],"IgG1":[124],"Fc":[125,267],"part":[126],"was":[128],"modified":[129],"by":[130,206],"amino":[131],"acid":[132],"exchange.":[133],"Compared":[134],"wild":[136],"type":[137],"RANK-Fc":[138],"protein":[140,275],"(RANK-Fc-WT),":[141],"our":[142,173,271],"mutant":[143],"RANK-Fc-ADCC":[144,191,240,273,297],"(S239D/I332E)":[145],"displayed":[146],"highly":[147],"enhanced":[148,230],"affinity":[149],"Fc\u03b3RIIIa":[151],"(CD16)":[152],"on":[153,216],"cells.":[155,208,238],"Primary":[156],"expressed":[159],"substantial":[160],"levels":[161],"53":[165],"78":[167],"(68%)":[168],"investigated":[169],"patient":[170,236],"cases,":[171],"RANK-Ig":[174],"bound":[177],"target":[183,256,288],"antigen-specific":[184],"manner.":[185],"Treatment":[186],"both":[188],"RANK-Fc-WT":[189,227],"clearly":[192],"reduced":[193],"release":[195],"RANKL-induced":[197],"immunomodulatory":[198],"factors":[199],"like":[200],"TNF,":[201],"IL-6,":[202],"IL-8":[203],"IL-10":[205],"When":[209],"ADCC":[219,245],"were":[220],"studied":[221],"found":[223],"treatment":[225,305],"only":[228],"slightly":[229],"against":[234],"RANKL-positive":[235],"However,":[239],"potently":[241],"induced":[242],"cytokine":[247,281],"production":[248],"response":[250],"targets":[253],"antigen-dependent":[257],"manner":[258],"due":[259],"functional":[262],"properties":[263],"its":[265],"engineered":[266],"moiety.":[268],"Taken":[269],"together,":[270],"Fc-engineered":[272],"may":[276],"serve":[277],"modulate":[279],"milieu":[282],"involved":[283],"pathophysiology":[286],"RANKL-expressing":[289],"reactivity.":[295],"Thus,":[296],"constitutes":[298],"attractive":[300],"immunotherapeutic":[301],"means":[302],"AML,":[307],"e.g.":[308],"elimination":[310],"minimal":[312],"residual":[313],"disease":[314],"after":[315],"conventional":[316],"therapy":[317],"including":[318],"SCT.":[319],"Disclosures:":[320],"No":[321],"relevant":[322],"conflicts":[323],"interest":[325],"declare.":[327]},"counts_by_year":[],"updated_date":"2026-09-22T06:50:58.402377","created_date":"2016-10-28T00:00:00"}